SCHEMBL23948294

SCHEMBL23948294

COc1cncc(-c2cnn(-c3cnn4ccc(=O)[nH]c34)c2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 7/20 0.38
CYP11B2 P19099 7/20 0.38
CYP1A2 P05177 4/20 0.38
CYP3A4 P08684 2/20 0.36
CYP2C9 P11712 2/20 0.36
PRMT5 O14744 1/20 0.36
WDR77 Q9BQA1 1/20 0.36
MKNK1 Q9BUB5 1/20 0.36
MKNK2 Q9HBH9 1/20 0.36
CYP2C19 P33261 1/20 0.35
PIK3CG P48736 2/20 0.35
ABL1 P00519 1/20 0.35
BCR P11274 1/20 0.35
GRM5 P41594 1/20 0.34
METAP2 P50579 1/20 0.34
RIPK2 O43353 2/20 0.33
CYP1A1 P04798 1/20 0.33
CYP1B1 Q16678 1/20 0.33
FYN P06241 1/20 0.33
PLAT P00750 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26306179 0.86 PRMT5 (0.33) CYP11B1CYP11B2PRMT5WDR77RIPK2
SCHEMBL23947985 0.84 PRMT5 (0.33) CYP11B1CYP11B2PRMT5WDR77ABL1
SCHEMBL26309079 0.83 HCAR1 (0.36) PLAT
SCHEMBL23948320 0.82 EGLN1 (0.32)
SCHEMBL23948444 0.81 KDR (0.31) MKNK2ABL1BCRPLATMAPKAPK2
SCHEMBL23947976 0.81 PRMT5 (0.36) CYP11B1CYP11B2PRMT5WDR77GRM5
SCHEMBL23947947 0.80 PLAT (0.41) MKNK1MKNK2GRM5PLAT
SCHEMBL23948322 0.79 MELK (0.40) CYP3A4CYP2C9PLAT
SCHEMBL23948323 0.79 MAPK1 (0.38) PRMT5WDR77MKNK1MKNK2PIK3CG
SCHEMBL23948328 0.79 ABL1 (0.38) CYP11B1CYP11B2CYP1A2CYP3A4ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242536-A1 METHODS FOR PREPARING TYROSINE RECEPTOR KINASE INHIBITORS PYRAMID BIOSCIENCES, INC. 2023-08-03 US disclosed
WO-2021211882-A1 METHODS FOR PREPARING TYROSINE RECEPTOR KINASE INHIBITORS PYRAMID BIOSCIENCES, INC. (US) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242536-A1 METHODS FOR PREPARING TYROSINE RECEPTOR KINASE INHIBITORS LTK, FRK, LCK CYP11B1 3594/4885CYP11B2 3875/4885CYP1A2 3815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.